S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
Log in
NASDAQ:GNPX

Genprex News Headlines

$4.90
+0.40 (+8.89 %)
(As of 03/5/2021 12:00 AM ET)
Add
Compare
Today's Range
$4.32
Now: $4.90
$4.99
50-Day Range
$3.75
MA: $5.34
$7.67
52-Week Range
$1.49
Now: $4.90
$7.72
Volume1.56 million shs
Average Volume1.77 million shs
Market Capitalization$212.06 million
P/E RatioN/A
Dividend YieldN/A
Beta-0.57

Headlines

Genprex (NASDAQ GNPX) News Headlines Today

Source:
SourceHeadline
Genprex, Inc. (NASDAQ:GNPX) Short Interest UpdateGenprex, Inc. (NASDAQ:GNPX) Short Interest Update
americanbankingnews.com - March 6 at 1:16 PM
Genprex (NASDAQ:GNPX) Shares Up 8.9%Genprex (NASDAQ:GNPX) Shares Up 8.9%
americanbankingnews.com - March 5 at 6:44 PM
Genprex (NASDAQ:GNPX) Stock Price Down 9.4%Genprex (NASDAQ:GNPX) Stock Price Down 9.4%
americanbankingnews.com - March 3 at 9:48 PM
BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Announces Participation Schedule for March Investor Conferences - StreetInsider.comBioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Announces Participation Schedule for March Investor Conferences - StreetInsider.com
streetinsider.com - March 1 at 7:47 PM
Genprex to Participate in Upcoming March Investor Conferences - Business WireGenprex to Participate in Upcoming March Investor Conferences - Business Wire
businesswire.com - March 1 at 2:47 PM
Genprex to Participate in Upcoming March Investor ConferencesGenprex to Participate in Upcoming March Investor Conferences
finance.yahoo.com - March 1 at 9:46 AM
Genprex (NASDAQ:GNPX) Trading Down 5.7%Genprex (NASDAQ:GNPX) Trading Down 5.7%
americanbankingnews.com - February 25 at 7:58 PM
Genprex (NASDAQ:GNPX) Trading 6% Higher Genprex (NASDAQ:GNPX) Trading 6% Higher
americanbankingnews.com - February 24 at 9:36 PM
Genprex (NASDAQ:GNPX) Stock Price Down 6.3%Genprex (NASDAQ:GNPX) Stock Price Down 6.3%
americanbankingnews.com - February 18 at 7:46 PM
Genprex Announces Formation of Clinical Advisory Board - Yahoo FinanceGenprex Announces Formation of Clinical Advisory Board - Yahoo Finance
finance.yahoo.com - February 10 at 7:37 PM
BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Forms Clinical Advisory Board, Announces $25M Registered Direct Offering - StreetInsider.comBioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Forms Clinical Advisory Board, Announces $25M Registered Direct Offering - StreetInsider.com
streetinsider.com - February 10 at 9:35 AM
Genprex, Inc. Announces $25 Million Registered Direct Offering Priced At-The-Market Under NASDAQ Rules, Without Warrants - Yahoo FinanceGenprex, Inc. Announces $25 Million Registered Direct Offering Priced At-The-Market Under NASDAQ Rules, Without Warrants - Yahoo Finance
finance.yahoo.com - February 10 at 9:35 AM
Proactive news headlines including Tocvan Ventures, HempFusion Wellness, Milestone Scientific and Esports Entertainment Group - StreetInsider.comProactive news headlines including Tocvan Ventures, HempFusion Wellness, Milestone Scientific and Esports Entertainment Group - StreetInsider.com
streetinsider.com - February 9 at 2:05 PM
Genprex, Inc. Announces $25 Million Registered Direct Offering Priced At-The-Market Under NASDAQ Rules, Without WarrantsGenprex, Inc. Announces $25 Million Registered Direct Offering Priced At-The-Market Under NASDAQ Rules, Without Warrants
finance.yahoo.com - February 9 at 9:04 AM
Genprex Announces Formation of Clinical Advisory Board - Business WireGenprex Announces Formation of Clinical Advisory Board - Business Wire
businesswire.com - February 9 at 12:02 AM
Genprex Announces Formation of Clinical Advisory BoardGenprex Announces Formation of Clinical Advisory Board
finance.yahoo.com - February 8 at 7:01 PM
BioMedNewsBreaks - Genprex Inc. (NASDAQ: GNPX) Joins Millions to Recognize World Cancer DayBioMedNewsBreaks - Genprex Inc. (NASDAQ: GNPX) Joins Millions to Recognize World Cancer Day
marketwatch.com - February 5 at 5:51 PM
Genprex Recognizes World Cancer Day - Yahoo FinanceGenprex Recognizes World Cancer Day - Yahoo Finance
finance.yahoo.com - February 5 at 2:49 AM
BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Joins Millions to Recognize World Cancer Day - StreetInsider.comBioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Joins Millions to Recognize World Cancer Day - StreetInsider.com
streetinsider.com - February 4 at 9:45 PM
Genprex Recognizes World Cancer Day - Business WireGenprex Recognizes World Cancer Day - Business Wire
businesswire.com - February 4 at 4:44 PM
Genprex Recognizes World Cancer DayGenprex Recognizes World Cancer Day
finance.yahoo.com - February 4 at 11:44 AM
Genprex Issues Shareholder Letter and Provides Corporate Update - Yahoo FinanceGenprex Issues Shareholder Letter and Provides Corporate Update - Yahoo Finance
finance.yahoo.com - February 1 at 11:19 PM
Genprex Issues Shareholder Letter and Provides Corporate UpdateGenprex Issues Shareholder Letter and Provides Corporate Update
finance.yahoo.com - February 1 at 6:18 PM
Genprex to Present at the Virtual Investor Conference Small and Microcap Showcase on February 4 - Yahoo FinanceGenprex to Present at the Virtual Investor Conference Small and Microcap Showcase on February 4 - Yahoo Finance
finance.yahoo.com - January 27 at 9:23 AM
Genprex to Present at the Virtual Investor Conference Small and Microcap Showcase on February 4Genprex to Present at the Virtual Investor Conference Small and Microcap Showcase on February 4
finance.yahoo.com - January 27 at 9:23 AM
Genprex to Present its Cutting-Edge Gene Therapies at the MoneyShow Accredited Investors Virtual Expo - Business WireGenprex to Present its Cutting-Edge Gene Therapies at the MoneyShow Accredited Investors Virtual Expo - Business Wire
businesswire.com - January 22 at 12:31 PM
Genprex to Present its Cutting-Edge Gene Therapies at the MoneyShow Accredited Investors Virtual ExpoGenprex to Present its Cutting-Edge Gene Therapies at the MoneyShow Accredited Investors Virtual Expo
finance.yahoo.com - January 21 at 9:23 AM
Genprex Achieves Major Manufacturing Milestone for REQORSA™ Immunogene Therapy for Upcoming Trials to Treat Non-Small Cell Lung Cancer - Business WireGenprex Achieves Major Manufacturing Milestone for REQORSA™ Immunogene Therapy for Upcoming Trials to Treat Non-Small Cell Lung Cancer - Business Wire
businesswire.com - January 14 at 9:47 PM
Genprex to Present at NobleCon17 on January 19 - Business WireGenprex to Present at NobleCon17 on January 19 - Business Wire
businesswire.com - January 14 at 4:30 PM
Genprex to Present at NobleCon17 on January 19Genprex to Present at NobleCon17 on January 19
finance.yahoo.com - January 14 at 4:30 PM
BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Passes Final Release Tests for Manufacturing Run of Proprietary Immunogene Therapy Treatment - StreetInsider.comBioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Passes Final Release Tests for Manufacturing Run of Proprietary Immunogene Therapy Treatment - StreetInsider.com
streetinsider.com - January 14 at 1:31 AM
Genprex achieves manufacturing milestone for immunogene therapy for upcoming lung cancer trials - Seeking AlphaGenprex achieves manufacturing milestone for immunogene therapy for upcoming lung cancer trials - Seeking Alpha
seekingalpha.com - January 13 at 8:30 PM
Genprex Achieves Major Manufacturing Milestone for REQORSA™ Immunogene Therapy for Upcoming Trials to Treat Non-Small Cell Lung Cancer - Yahoo FinanceGenprex Achieves Major Manufacturing Milestone for REQORSA™ Immunogene Therapy for Upcoming Trials to Treat Non-Small Cell Lung Cancer - Yahoo Finance
finance.yahoo.com - January 13 at 10:29 AM
Genprex Achieves Major Manufacturing Milestone for REQORSA™ Immunogene Therapy for Upcoming Trials to Treat Non-Small Cell Lung CancerGenprex Achieves Major Manufacturing Milestone for REQORSA™ Immunogene Therapy for Upcoming Trials to Treat Non-Small Cell Lung Cancer
finance.yahoo.com - January 13 at 10:29 AM
Form SC 13G/A Genprex, Inc. Filed by: SABBY MANAGEMENT, LLC - StreetInsider.comForm SC 13G/A Genprex, Inc. Filed by: SABBY MANAGEMENT, LLC - StreetInsider.com
streetinsider.com - January 4 at 3:02 PM
The best-performing Austin stocks in 2020 - Austin Business JournalThe best-performing Austin stocks in 2020 - Austin Business Journal
bizjournals.com - December 29 at 6:22 PM
Genprex, Inc. Announces Closing Of $12 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules Without Warrants - Business WireGenprex, Inc. Announces Closing Of $12 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules Without Warrants - Business Wire
businesswire.com - December 25 at 2:35 AM
Genprex, Inc. Announces Closing Of $12 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules Without Warrants - Yahoo FinanceGenprex, Inc. Announces Closing Of $12 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules Without Warrants - Yahoo Finance
finance.yahoo.com - December 24 at 4:34 PM
BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Enters into Estimated $12-Million Securities Purchase Agreement - StreetInsider.comBioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Enters into Estimated $12-Million Securities Purchase Agreement - StreetInsider.com
streetinsider.com - December 24 at 6:33 AM
Lets Look at the Big Picture of GenprexLet's Look at the Big Picture of Genprex
finance.yahoo.com - December 23 at 12:45 PM
Genprex, Inc. Announces $12 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules, Without Warrants - Business WireGenprex, Inc. Announces $12 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules, Without Warrants - Business Wire
businesswire.com - December 23 at 7:44 AM
12 Health Care Stocks Moving In Tuesdays Intraday Session - Benzinga12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
benzinga.com - December 23 at 12:42 AM
Genprex launches $12M ATM equity offering - Seeking AlphaGenprex launches $12M ATM equity offering - Seeking Alpha
seekingalpha.com - December 23 at 12:42 AM
Genprex Completes Manufacturing Scale-Up for Clinical-Grade Production of REQORSA™ Immunogene Therapy for Upcoming Acclaim-1 and Acclaim-2 Clinical Trials For Lung Cancer - Yahoo FinanceGenprex Completes Manufacturing Scale-Up for Clinical-Grade Production of REQORSA™ Immunogene Therapy for Upcoming Acclaim-1 and Acclaim-2 Clinical Trials For Lung Cancer - Yahoo Finance
finance.yahoo.com - December 22 at 2:39 PM
Genprex Completes Manufacturing Scale-Up for Clinical-Grade Production of REQORSA™ Immunogene Therapy for Upcoming Acclaim-1 and Acclaim-2 Clinical Trials For Lung Cancer - Business WireGenprex Completes Manufacturing Scale-Up for Clinical-Grade Production of REQORSA™ Immunogene Therapy for Upcoming Acclaim-1 and Acclaim-2 Clinical Trials For Lung Cancer - Business Wire
businesswire.com - December 22 at 9:38 AM
Genprex Completes Manufacturing Scale-Up for Clinical-Grade Production of REQORSA™ Immunogene Therapy for Upcoming Acclaim-1 and Acclaim-2 Clinical Trials For Lung CancerGenprex Completes Manufacturing Scale-Up for Clinical-Grade Production of REQORSA™ Immunogene Therapy for Upcoming Acclaim-1 and Acclaim-2 Clinical Trials For Lung Cancer
finance.yahoo.com - December 22 at 9:38 AM
Genprex (GNPX) Looks Good: Stock Adds 6.5% in Session - Yahoo FinanceGenprex (GNPX) Looks Good: Stock Adds 6.5% in Session - Yahoo Finance
finance.yahoo.com - December 17 at 1:30 PM
Genprex Completes Manufacturing Technology Transfer for Novel Gene Therapy - Business WireGenprex Completes Manufacturing Technology Transfer for Novel Gene Therapy - Business Wire
businesswire.com - December 8 at 9:28 AM
Genprex Completes Manufacturing Technology Transfer for Novel Gene TherapyGenprex Completes Manufacturing Technology Transfer for Novel Gene Therapy
finance.yahoo.com - December 8 at 9:28 AM
Genprex to Present at the Benzinga Global Small Cap Conference on December 8 - Business WireGenprex to Present at the Benzinga Global Small Cap Conference on December 8 - Business Wire
businesswire.com - December 4 at 6:28 PM
This page was last updated on 3/7/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.